Ist diese Aktie ein Drohnen Hersteller? - 500 Beiträge pro Seite

ISIN: US46564C2035 | WKN: A2N727 | Symbol: INLB
Nasdaq OTC
-8,00 %
-0,100 USD

Beitrag schreiben

Begriffe und/oder Benutzer


Wer kennt diese Aktie, im Moment werden einige Drohnen Aktien gesucht, eine
davon heißt Aireware.
AirWare Labs Files Patent Application for 'Revolutionary Oxygen Cannula Delivery System', New Nasal Cannula System Will Resolve Common Patient Complaints +Improve the Effectiveness of Oxygen Therapy…

"SCOTTSDALE, AZ--(Marketwired - Jul 9, 2014) - AirWare Labs Corp. (OTCQB: AIRW) today announced the filing of a new patent application for a revolutionary oxygen cannula delivery system, expected to launch later this year. The system will feature a proprietary cannula design, fitted with disposable nasal dilators that diffuse the stream of oxygen as it enters the nasal passage and prevent the nasal dryness, irritation and discomfort commonly reported by cannula users. The nasal dilators also work to open the nasal passage and increase airflow by up to 60%, enhancing the overall effectiveness of oxygen therapy.

Commonly prescribed for patients with chronic shortness of breath, sleep-related breathing disorders and chronic obstructive pulmonary disease (COPD), oxygen therapy has been widely provided through a nasal cannula system since the 1940s. Largely unchanged since its inception nearly 75 years ago, the traditional nasal cannula causes a myriad of patient complaints, including nasal passage dryness, irritation and failure to stay in place while the patient is asleep. In addition, the potential for contamination and infection from improperly cleaned cannulas is a pervading problem.

According to the National Heart, Lung and Blood Institute, over 12 million people in the U.S. have been diagnosed with COPD and an additional 12 million are likely to have it without realizing it. A recent international survey found that worldwide prevalence ranged from 7%-9% (up to 640 million people). With home oxygen patients averaging two or three cannulas a month, an estimated 800 million cannulas are used annually for oxygen therapy alone.

"With millions of people worldwide using nasal cannulas for oxygen therapy, it's surprising that the same issues with dryness and irritation have persisted since the 1940s," said Jeffrey Rassás, CEO of AirWare Labs. "We're very excited to bring to market a highly effective solution for these common complaints that will also significantly lower the risk of infection or contamination. The diffused air stream will greatly reduce dryness, and the inserts are designed to hold the cannula in place while the oxygen recipient is sleeping."

The global market for respiratory care devices, including oxygen cannulas, is expected to reach $13.5 billion by 2015, according to market research and consulting company MarketsandMarkets.

About AirWare Labs Corporation:

AirWare Labs Corp., publicly traded as (OTCQB: AIRW), provides patented and innovative technology solutions for consumer products that promote better health through breathing and enhanced wellbeing. AirWare Labs' products are marketed under the brand name of AIR®. AIR® products utilize an FDA approved medical grade material, molded as an intranasal Air Breathe dilator, to act as the delivery system. This AIR® microstructure enhances normal nasal airflow with every breath -- clinically proven to deliver up to 40% more oxygen.

Some AIR® products are infused with essential oils with unique healing properties including antibacterial and therapeutic defense against airborne allergens, viruses and bacteria. AIR® Allergy and Travel products provide additional defense in the form of an integrated filter media from 3M to remove microscopic particles that carry viruses, allergens and bacteria. Other AIR® specialty products help provide performance enhancements and relief from congestion, insomnia, headaches, nausea, and snoring. For more product information, please visit: or company information visit: "

Beitrag zu dieser Diskussion schreiben

Es handelt sich hier um eine ältere Diskussion, daher ist das Schreiben in dieser Diskussion nicht mehr möglich. Bitte eröffnen Sie hier eine neue Diskussion.